SPDR S&P Biotech ETF
180 hedge funds and large institutions have $2.76B invested in SPDR S&P Biotech ETF in 2015 Q1 according to their latest regulatory filings, with 50 funds opening new positions, 48 increasing their positions, 47 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
2% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 47
65% less call options, than puts
Call options by funds: $245M | Put options by funds: $701M
74.31% less ownership
Funds ownership: 463.38% → 389.07% (-74%)
Holders
180
Holding in Top 10
10
Calls
$245M
Puts
$701M
Top Buyers
| 1 | +$115M | |
| 2 | +$114M | |
| 3 | +$113M | |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$73.7M |
| 5 |
Goldman Sachs
New York
|
+$72.3M |
Top Sellers
| 1 | -$205M | |
| 2 | -$178M | |
| 3 | -$17.8M | |
| 4 |
SCM
Sandler Capital Management
New York
|
-$8.13M |
| 5 |
VF
Virtu Financial
New York
|
-$5.93M |